NCT06617949 Evaluating Pain Control Strategies in Postpartum Patients on Opioid Use Disorder Medications.
| NCT ID | NCT06617949 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Medical College of Wisconsin |
| Condition | Substance Use Disorder (SUD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-01-16 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2025-01-16 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to investigate the efficacy of three different modalities of post-operative pain control in parturient with opioid use disorders. The investigators aim to determine whether the different approach utilized show better outcomes with pain management and if there are any association with reduction of symptoms of anxiety, depression, and overall well-being.
Eligibility Criteria
Inclusion Criteria: * Inclusion criteria include being a parturient with Substance use disorder (SUD) and age 18-35 Exclusion Criteria: * Exclusion criteria include having a diagnosed medical condition(allergies to medication, pathology such as severe aortic stenosis excluding patients from receiving an epidural etc) that will exempt patient from intervention arm of the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06617949 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Substance Use Disorder (SUD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06617949 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06617949 currently recruiting?
Yes, NCT06617949 is actively recruiting participants. Contact the research team at maalbrecht@mcw.edu for enrollment information.
Where is the NCT06617949 trial being conducted?
This trial is being conducted at Milwaukee, United States, Milwaukee, United States.
Who is sponsoring the NCT06617949 clinical trial?
NCT06617949 is sponsored by Medical College of Wisconsin. The trial plans to enroll 20 participants.